Dr Tim Paget
Tim is a commercially aware physician who has led medical departments and teams responsible for clinical research, pharmacovigilance, medical information, biometrics and medical/scientific liaison. His experience includes HTA submissions, hosting conferences and advisory boards, negotiating with regulatory authorities and Code of Practice authorities, as well as medical support within joint ventures and leading medical teams in environments of culture and structure change. Tims product launch experience has included the blockbusting lipid-lowering agent, Lipitor (Parke-Davis/Pfizer), Thalidomide Pharmion, and a number of line extensions including two other major oncology products.
Tims work as a consultant has included leading the UK Medical Department and providing strategic input as part of the UK Leadership Team for Celgene during the integration of Pharmion and 2 major product launches, supporting Solvay with Code of Practice and SOP development, training and coaching during PMCPA audits and developing the medical function for AAA (a Novartis Company) and launch of their Radioligand Therapy.
Pharmaceutical Industry Appointments
2001-2008:Freelance Consultant (Director: Navigate Medical Limited)Providing Pharmaceutical Consultancy, project management and training in the pharmaceutical industry.Client companies have included Janssen-Cilag, Novartis, Eisai, Wyeth and Ortho Biotech.Projects have included pre-launch and launch activities, interim positions (Medical Director, Director of Specialist Medicine, Medical Affairs Manager) Medical Communications and Issues Management, NICE/SMC submissions and Key Opinion Leader development
January 2005-March 2007:Medical Director ICON Consulting
Reporting to the Vice President for European Consulting. Supporting the delivery of early phase research and consulting services in Europe including regulatory and medical affairs. Development of new service initiatives including orphan drug submissions and PIL user testing, support for development and growth of the business.
1999-2001:Head of Medical Affairs Clinical Trial Unit, Janssen-Cilag
Reporting to the Medical Director.Overall responsibility for four Medical Department teams: Clinical Research, Biometrics, Medical Affairs and the newly developed Medical and Scientific Liaison Unit, a full team of 20, which included 5 direct reports.Therapeutic areas including, C.N.S., G.I. and Female healthcare.The Unit whilst being part of the medical group is highly integrated with the marketing and sales functions both at the level of the management team and the team members (CRAs and Scientific Liaison Managers) in the field.Additional interim management of Pharmacovigilance during a time of change while the department was being incorporated into a new global function.
1998-1999:Head of Medical Affairs, Parke Davis (UK and Ireland)
Reporting to the Medical Director.Responsible for the management and training of the team often Medical Advisers and Medical Information Executives.The team worked within a matrix structure responsible for: input into clinical trial design (Phase III-IV), work with investigators/study monitoring team, contributing to formulation and approval of promotional material, regulatory/product labelling advice and expert reports.The emphasis being on key brands in the CVS and CNS therapy areas.
1997-1998:Senior Medical Adviser, Parke Davis (UK and Ireland)
Reporting to the Medical Director, responsible for the management and training of a new Medical Adviser/Drug Safety Manager and overall supervisory responsibility for Medical Affairs/Drug Safety. Including formulation and approval of promotional material, regulatory/product labelling advice and expert reports. The emphasis was on key brands in the CVS and CNS therapy areas and contribution on the Global Drug Safety Surveillance Board.
1995-1996:Medical Adviser, Parke Davis (UK and Ireland)
Reporting to the Head of Clinical Affairs.Responsible for Marketing, Regulatory and Clinical Research team support for all brands.Management of the Drug Safety/GCP Executive
Academic Appointments/Lecturing
University of Wales/BrAPP:
Diploma Pharmaceutical Medicine course.Preparing and delivering 3 hour Medical-Marketing workshop.Co-ordination of Module 4.
ACRP:
HMT for Pharmaceutical Physicians: Healthcare Marketplace Module. Lecturing and workshop training in Medical-Marketing and management of medico-legal review
Faculty of Pharmaceutical Medicine (Royal College of Physicians):
Senior Speciality Advisor
Clinical Posts
1999-2001: G.P. (single sessions) St Clements Surgery, Winchester.
1994-1995: G.P. Registrar; Haslemere Health Centre, Haslemere, Surrey.
1993-1994: SHO Medicine; Royal Surrey County Hospital, Guildford
1993: SHO Obstetrics & Gynaecology; St. Peters Hospital, Chertsey.
1992-1993: SHO Paediatrics/Neonatology; St. Richard’s Hospital, Chichester, 1992-1993: West Sussex.Community Medical Officer; Chichester
1992: SHO A&E; Worthing Hospital, Worthing, West Sussex.
1991-1992: SHO General Medicine SHO Psychiatry.
1991: House Surgeon; Worthing Hospital, Worthing, West Sussex.
1990-1991: House Physician; King Edward VII Hospital
1990-1991: House Physician Douglas Macmillan Continuing Care Service
Education & Qualifications
1997: Diploma in Pharmaceutical Medicine.
1990-1995: General Practitioner Training, Diploma of the Faculty of Family Planning, Child Health Surveillance and Minor Surgery Registration.
1984-1990: Bachelor of Medicine, Bachelor of Surgery; St. George’s Hospital Medical School, University of London.
Membership of Professional Associations
1997 – 2022:
Fellow of the Faculty of Pharmaceutical Medicine (Royal College of Physicians)
1996 – 2001:
Elected Executive Committee Member for BrAPP.
2001 – 2003:
Deputy Chairman - British Association of Pharmaceutical Physicians.